The “Advances in Liquid Biopsy Platforms” report has been added to Research and Markets’ offering.
This Genetic Technology TOE depicts trends across liquid biopsy platforms. The advent of novel antibody-based and targeted small molecule therapies have greatly improved the management of cancer disease. However, there is a growing need for robust monitoring platforms for enhanced assessment of diseases progression and treatment monitoring in cancer patients.
Lung cancer clinical trials using liquid biopsy platforms are depicted along with industry interactions.
The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions.
The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.
The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Key Topics Covered:
1. Recent Innovations in Liquid Biopsy Platforms
– Novel Liquid Biopsy Platform for Cancer Monitoring
– Analyzing Free-floating Genome for Early Cancer Detection
– Circulating Tumor DNA for Monitoring Chronic Lymphocytic Leukemia
– Extracellular Vesicle Isolation Technology for Liquid Biopsy Applications
2. Clinical Trial Analysis and Industry Interactions
– Clinical Trial Analysis
– Industry Interactions
For more information about this report visit https://www.researchandmarkets.com/research/c3jnsr/advances_in